RxDoctor Payments Data

Jeff Chen, MD

Physical Medicine & Rehabilitation · Walnut Creek, CANPI 1922202407

Payments from drug & device makers

$2,989in general payments, 2019–2025

Across 132 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$1K
  • AbbVie$204
  • Collegium Pharmaceutical, Inc.$164
  • Scilex Pharmaceuticals Inc.$154
  • Pfizer$154
  • Saluda Medical Americas, Inc.$153
  • plus $751 from 16 others

What the payments were for

  • Food & beverage$2,89597%
  • Education$943%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,989 in reported general payments places this provider in the 85th percentile of 830 physical medicine & rehabilitation providers in California.

See all physical medicine & rehabilitation providers in California

Medicare billing

Part B allowed, 2024
$219,392
Medicare patients
156
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl23$16,504
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen399$14,054
Buprenorphine20$8,549
Sumatriptan Succinate11$4,821
Morphine Sulfate ErMorphine Sulfate81$2,621
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen113$2,242
Naloxone Hcl30$2,062
Lidocaine20$2,046
Cyclobenzaprine Hcl101$1,530
Oxycodone Hcl105$1,453
Gabapentin123$1,386
Tramadol Hcl ErTramadol Hcl24$1,314
Duloxetine Hcl45$811
Pregabalin66$803
Fentanyl12$705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$164$16,50423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 830 physical medicine & rehabilitation providers in California.

Other physical medicine & rehabilitation in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →